GlassScriptPhysician profile
David L Dunlap
NPI 1881654044
$6,630.14
in general payments reported to CMS, 2019-2025
46 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $465 · 2021: $1,370 · 2022: $1,230 · 2023: $1,025 · 2024: $1,712 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.35 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $834.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $580.84 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $407.43 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $373.64 | 2021-2024 | Ajovy, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $363.86 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.98 | 2020-2025 | Xifaxan |
| Pfizer INC. | $301.60 | 2019-2025 | |
| Abbott Laboratories | $217.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Supernus Pharmaceuticals, INC. | $204.31 | 2023-2024 | Qelbree, Qelbree |
| Amgen INC. | $193.29 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $186.57 | 2019-2025 | Xarelto, Spravato |
| Stryker Corporation | $104.72 | 2022 | |
| Amarin Pharma, INC. | $89.64 | 2020-2021 | |
| Ardelyx, INC. | $77.94 | 2024 | Ibsrela |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.